Skip to main content
Top
Published in: Gut Pathogens 1/2021

Open Access 01-12-2021 | Ulcerative Colitis | Research

Retrospective analysis of Clostridioides difficile and other intestinal infections in patients with Crohn’s disease and ulcerative colitis in the tertiary hospital in Poland. POLIBD survey results

Authors: Jolanta Gruszecka, Rafał Filip

Published in: Gut Pathogens | Issue 1/2021

Login to get access

Abstract

Background

There are several studies which evaluated the number of infections caused by enteric pathogens, including Clostridioides difficile in patients with inflammatory bowel disease (IBD). Our aim was to assess the prevalence of intestinal infections among patients suffering from IBD, when admitted to the hospital due to exacerbation of the disease.

Results

The performed, retrospective analysis covered test results for C. difficile toxins A and B along with rectal swab cultures sampled from patients, treated in a tertiary IBD center in Poland, between 2017 and 2019. Main objective was to estimate the presence of any infection, which could imitate or co-exist along with the exacerbation of the IBD. All in all 1471 patients had microbiological tests performed, including 1112 tested for C. difficile toxins A and B; and 359 patients who had rectal swab culture. Positive test results for C. difficile toxins A and B were reported in 358 cases, positive results from rectal swab culture were confirmed altogether in case of 25 samples. As far as patients with IBD are concerned, positive results for C. difficile toxins A and B were detected in 82 cases, positive results in rectal swab culture from patients with IBD were reported in 20 cases.

Conclusion

Intestinal infections were reported in 14.9% of patients (102/685) with IBD symptoms. Positive test results for C. difficile toxins A and B and rectal swab cultures among patients without IBD symptoms were reported in 35.7% of cases (281/786). Intestinal superinfections may complicate the clinical picture of IBD patients, increasing the diagnostic and therapeutic burden. Appropriate early procedures are thus needed in these patients.
Literature
1.
go back to reference Moćko P, Kawalec P, Pilc A. Inflammatory bowel diseases (IBD) as public health problem—review of the literaturę. Med Rodz. 2016;19(4):244–54. Moćko P, Kawalec P, Pilc A. Inflammatory bowel diseases (IBD) as public health problem—review of the literaturę. Med Rodz. 2016;19(4):244–54.
2.
go back to reference Badurek S, Muszytowski M, Stróżecki P, Manitius J. Clostridium difficile-associated disease in patients with chronic kidney disease. Forum Nefrol. 2016;9(3):141–8. Badurek S, Muszytowski M, Stróżecki P, Manitius J. Clostridium difficile-associated disease in patients with chronic kidney disease. Forum Nefrol. 2016;9(3):141–8.
3.
go back to reference Martirosian G. Laseczki Gram-dodatnie wytwarzające spory/gram-positive bacilli that produce spores. In: Heczko PB, Wróblewska M, Pietrzyk A, editors. Medical microbiology. Warsaw: PZWL (National Institute of Medical Publications); 2014. p. 129–36. Martirosian G. Laseczki Gram-dodatnie wytwarzające spory/gram-positive bacilli that produce spores. In: Heczko PB, Wróblewska M, Pietrzyk A, editors. Medical microbiology. Warsaw: PZWL (National Institute of Medical Publications); 2014. p. 129–36.
6.
go back to reference Mylonaki M, Langmead L, Pantes A, et al. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol. 2004;16(8):775–8.CrossRef Mylonaki M, Langmead L, Pantes A, et al. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol. 2004;16(8):775–8.CrossRef
7.
go back to reference Grant EB, Hendler S, Okafor P, et al. Rising incidence of intestinal infections in inflammatory bowel disease: a nationwide analysis. Inflamm Bowel Dis. 2018;24(8):1849–56.CrossRef Grant EB, Hendler S, Okafor P, et al. Rising incidence of intestinal infections in inflammatory bowel disease: a nationwide analysis. Inflamm Bowel Dis. 2018;24(8):1849–56.CrossRef
8.
go back to reference Jordan EA, Joelson A, Green P, et al. Enteric infections are common in patients with flares of inflammatory bowel disease. Am J Gastroenterol. 2018;113(10):1530–9.CrossRef Jordan EA, Joelson A, Green P, et al. Enteric infections are common in patients with flares of inflammatory bowel disease. Am J Gastroenterol. 2018;113(10):1530–9.CrossRef
9.
go back to reference Axelrad JE, Olén O, Askling J, et al. Gastrointestinal infection increases odds of inflammatory bowel disease in a nationwide case-control study. Clin Gastroenterol Hepatol. 2019;17(7):1311–22.CrossRef Axelrad JE, Olén O, Askling J, et al. Gastrointestinal infection increases odds of inflammatory bowel disease in a nationwide case-control study. Clin Gastroenterol Hepatol. 2019;17(7):1311–22.CrossRef
10.
go back to reference Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009;3:46–91.CrossRef Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009;3:46–91.CrossRef
11.
go back to reference Navarro-Llavat M, Domènech E, Bernal I, et al. Prospective, observational, cross-sectional study of intestinal infections among acutely active inflammatory bowel disease patients. Digestion. 2009;80:25–9.CrossRef Navarro-Llavat M, Domènech E, Bernal I, et al. Prospective, observational, cross-sectional study of intestinal infections among acutely active inflammatory bowel disease patients. Digestion. 2009;80:25–9.CrossRef
12.
go back to reference Xu H, Tang H, Xu T, et al. Retrospective analysis of Clostridium difficile infection in patients with ulcerative colitis in a tertiary hospital in China. BMC Gastroenterol. 2019;19:3.CrossRef Xu H, Tang H, Xu T, et al. Retrospective analysis of Clostridium difficile infection in patients with ulcerative colitis in a tertiary hospital in China. BMC Gastroenterol. 2019;19:3.CrossRef
14.
go back to reference Pfaller MA, Diekeman DJ, Procop GW, et al. Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp. J Clin Mikrobiol. 2007;45(11):3522–8.CrossRef Pfaller MA, Diekeman DJ, Procop GW, et al. Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp. J Clin Mikrobiol. 2007;45(11):3522–8.CrossRef
15.
go back to reference Nguyen GC, Kaplan GG, Harris ML, et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103(6):1443–50.CrossRef Nguyen GC, Kaplan GG, Harris ML, et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103(6):1443–50.CrossRef
16.
go back to reference Issa M, Vijayapal A, Graham MB, Beaulieu DB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5(3):345–51.CrossRef Issa M, Vijayapal A, Graham MB, Beaulieu DB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5(3):345–51.CrossRef
17.
go back to reference Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015;373(3):287–8.PubMed Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015;373(3):287–8.PubMed
18.
go back to reference Ziółkowski G, Ziółkowska B, Ochocka B. Infekcje Clostridium difficile, niedoceniane zakażenia w aspekcie klinicznym i epidemiologicznym/Clostridium difficile infections, underestimated infections in the clinical and epidemiological aspect. Polskie Stowarzyszenie Pielęgniarek Epidemiologicznych/Polish Association of Epidemiological Nurses, Katowice; 2012. Ziółkowski G, Ziółkowska B, Ochocka B. Infekcje Clostridium difficile, niedoceniane zakażenia w aspekcie klinicznym i epidemiologicznym/Clostridium difficile infections, underestimated infections in the clinical and epidemiological aspect. Polskie Stowarzyszenie Pielęgniarek Epidemiologicznych/Polish Association of Epidemiological Nurses, Katowice; 2012.
19.
go back to reference Albrecht P, Pituch H. Clostridium difficile—a growing diagnostic and therapeutic problem. Onkol Prak Klin. 2013;9(1):22–31. Albrecht P, Pituch H. Clostridium difficile—a growing diagnostic and therapeutic problem. Onkol Prak Klin. 2013;9(1):22–31.
20.
go back to reference Trifan A, Stanciu C, Stoica O, et al. Impact of Clostridium difficile infection on inflammatory bowel disease outcome: a review. World J Gastroenterol. 2014;20(33):11736–42.CrossRef Trifan A, Stanciu C, Stoica O, et al. Impact of Clostridium difficile infection on inflammatory bowel disease outcome: a review. World J Gastroenterol. 2014;20(33):11736–42.CrossRef
21.
go back to reference Czepiel J, Biesiada G, Perucki W, et al. Clostridium difficile infection in patients with inflammatory bowel disease. Prz Gastroenterol. 2014;9(3):125–9.PubMedPubMedCentral Czepiel J, Biesiada G, Perucki W, et al. Clostridium difficile infection in patients with inflammatory bowel disease. Prz Gastroenterol. 2014;9(3):125–9.PubMedPubMedCentral
22.
go back to reference Azie N, Neofytos D, Pfaller M, et al. The PATH (prospective antifungal therapy) alliance registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis. 2012;73:293–300.CrossRef Azie N, Neofytos D, Pfaller M, et al. The PATH (prospective antifungal therapy) alliance registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis. 2012;73:293–300.CrossRef
23.
go back to reference Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol. 2012;107:1409–22.CrossRef Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol. 2012;107:1409–22.CrossRef
24.
go back to reference Toruner M, Loftus EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterol. 2008;134:929–36.CrossRef Toruner M, Loftus EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterol. 2008;134:929–36.CrossRef
25.
go back to reference Park MA, Li JT, Hagan JB, et al. Common variable immunodeficiency: a new look at an old disease. Lancet. 2008;372:489–502.CrossRef Park MA, Li JT, Hagan JB, et al. Common variable immunodeficiency: a new look at an old disease. Lancet. 2008;372:489–502.CrossRef
26.
go back to reference Scott M, Hammer SM. Management of newly diagnosed HIV infection. N Engl J Med. 2005;353:1702–10.CrossRef Scott M, Hammer SM. Management of newly diagnosed HIV infection. N Engl J Med. 2005;353:1702–10.CrossRef
27.
go back to reference Dave M, Purohit T, Razonable R, et al. Opportunistic infections due to inflammatory bowel disease therapy. Inflamm Bowel Dis. 2014;20:196–212.CrossRef Dave M, Purohit T, Razonable R, et al. Opportunistic infections due to inflammatory bowel disease therapy. Inflamm Bowel Dis. 2014;20:196–212.CrossRef
28.
go back to reference Antonelli E, Baldoni M, Giovenali P, et al. Intestinal superinfections in patients with inflammatory bowel diseases. J Crohns Colitis. 2012;6:154–9.CrossRef Antonelli E, Baldoni M, Giovenali P, et al. Intestinal superinfections in patients with inflammatory bowel diseases. J Crohns Colitis. 2012;6:154–9.CrossRef
29.
go back to reference Kirchgesner J, Lemaitre M, Carrat F, et al. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology. 2018;155:337–46.CrossRef Kirchgesner J, Lemaitre M, Carrat F, et al. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology. 2018;155:337–46.CrossRef
30.
go back to reference Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8:443–68.CrossRef Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8:443–68.CrossRef
31.
go back to reference Zhang S, Palazuelos-Munoz S, Balsells EM, et al. Cost of hospital management of Clostridium difficile infection in United States—a meta-analysis and modelling study. BMC Infect Dis. 2016;16(1):447.CrossRef Zhang S, Palazuelos-Munoz S, Balsells EM, et al. Cost of hospital management of Clostridium difficile infection in United States—a meta-analysis and modelling study. BMC Infect Dis. 2016;16(1):447.CrossRef
34.
go back to reference Le Monnier A, Duburcq A, Zahar JR, et al. Hospital cost of Clostridium difficile infection including the contribution of recurrences in French acute-care hospitals. J Hosp Infect. 2015;91(2):117–22.CrossRef Le Monnier A, Duburcq A, Zahar JR, et al. Hospital cost of Clostridium difficile infection including the contribution of recurrences in French acute-care hospitals. J Hosp Infect. 2015;91(2):117–22.CrossRef
35.
go back to reference Zimlichman E, Henderson D, Tamir O, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med. 2013;173(22):2039–46.CrossRef Zimlichman E, Henderson D, Tamir O, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med. 2013;173(22):2039–46.CrossRef
36.
go back to reference Ahmad S, Khan Z. Invasive candidiasis: a review of nonculture-based laboratory diagnostic methods. Indian J Med Microbiol. 2012;30:264–9.CrossRef Ahmad S, Khan Z. Invasive candidiasis: a review of nonculture-based laboratory diagnostic methods. Indian J Med Microbiol. 2012;30:264–9.CrossRef
37.
go back to reference Lévêque N, Brixi-Benmansour H, Reig T, et al. Low frequency of cytomegalovirus infection during exacerbations of inflammatory bowel diseases. J Med Virol. 2010;82:1694–700.CrossRef Lévêque N, Brixi-Benmansour H, Reig T, et al. Low frequency of cytomegalovirus infection during exacerbations of inflammatory bowel diseases. J Med Virol. 2010;82:1694–700.CrossRef
Metadata
Title
Retrospective analysis of Clostridioides difficile and other intestinal infections in patients with Crohn’s disease and ulcerative colitis in the tertiary hospital in Poland. POLIBD survey results
Authors
Jolanta Gruszecka
Rafał Filip
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Gut Pathogens / Issue 1/2021
Electronic ISSN: 1757-4749
DOI
https://doi.org/10.1186/s13099-021-00471-z

Other articles of this Issue 1/2021

Gut Pathogens 1/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.